TICKERNERD
Menu
HRMYHRMYHealthcare · Biotechnology

HRMY Stock Forecast: Harmony Biosciences Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$38
−0.99% on the day

The 10 Wall Street analysts covering Harmony Biosciences Holdings, Inc. hold a median 12-month price target of $48 — +24.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
84 / 100
Median analyst target
$48
Analysts covering
10
Total return, dividends reinvested
1W
−0.8%
1M
+9.5%
YTD
+1.9%
1Y
+4.4%
From 52W high
−5.9%
From 52W low
+47.2%
$26
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HRMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Harmony Biosciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Quality
83
Volatility
82
Revisions
80
Growth
52
Issuance
52
Momentum
51
Accruals
47
Size
35

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HRMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HRMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26HRMYHigh $70Median $48Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
6 Buy3 Hold1 Sell
Low $30Median $48High $70

The green dot is the last close — the median target sits +24.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Truist SecuritiesMaintainsHold$29 → $34
4 Aug 2026NeedhamMaintainsBuy$45 → $50
31 July 2026MizuhoMaintainsOutperform$50 → $51
16 July 2026HC Wainwright & Co.ReiteratesBuy$55
16 July 2026HC Wainwright & Co.ReiteratesBuy—
30 June 2026Deutsche BankMaintainsHold—
8 May 2026Truist SecuritiesMaintainsHold—
25 Feb 2026B of A SecuritiesMaintainsUnderperform—
25 Feb 2026HC Wainwright & Co.ReiteratesBuy—
25 Feb 2026NeedhamMaintainsBuy—
25 Feb 2026UBSMaintainsNeutral—
11 Feb 2026UBSDowngradeNeutral—
8 Jan 2026Truist SecuritiesMaintainsBuy—
1 Dec 2025MizuhoMaintainsOutperform—
24 Nov 2025HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025NeedhamReiteratesBuy—
6 Nov 2025MizuhoMaintainsOutperform—
15 Oct 2025UBSMaintainsBuy—
25 Sept 2025Deutsche BankMaintainsBuy—
25 Sept 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HRMY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HRMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+9.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Harmony Biosciences Holdings, Inc. (HRMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.5×

Cheaper than 54% of US stocks

Price / sales
2.3×

Cheaper than 50% of US stocks

Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
6.7×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
30.3%

Higher than 79% of US stocks

Earnings growth (YoY)
89.6%

Higher than 83% of US stocks

Gross margin
75.8%

Higher than 88% of US stocks

Operating margin
34.2%

Higher than 89% of US stocks

Net margin
18.9%

Higher than 82% of US stocks

Returns & dividend
Return on equity
20.5%

Higher than 82% of US stocks

Return on assets
11.6%

Higher than 94% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HRMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HRMYHarmony Biosciences Holdings, Inc.$2.2B
84
RAPPRapport Therapeutics, Inc.$2.2B
42
VERAVera Therapeutics, Inc.$2.2B
27
KLRAKailera Therapeutics, Inc.$2.2B
1
PGENPrecigen, Inc.$2.2B
80
PVLAPalvella Therapeutics, Inc.$2.2B
33
VCELVericel Corp.$2.2B
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Harmony Biosciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HRMY news & analysis

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

MarketBeat · 14 Aug 2026positive

At Piper Sandler's virtual CNS Symposium, Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy, and pitolisant lifecycle-management programs.

Why it matters — A Harmony Biosciences watcher would care because the company's record WAKIX quarterly results and progress across its orexin, epilepsy, and pipeline programs indicate ongoing momentum in its core narcolepsy franchise and future development plans.

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Zacks Investment Research · 7 Aug 2026positive

Zacks Investment Research highlighted HRMY among four healthcare stocks to watch as defensive demand strengthens in 2026, citing improving earnings outlooks and steady sector momentum for the group.

Why it matters — HRMY watchers would care because the item places the company among healthcare names with improving earnings outlooks amid strengthening defensive demand.

4 Stocks Trading Near 52-Week High With More Upside Potential

Zacks Investment Research · 6 Aug 2026positive

Zacks Investment Research identified HRMY as one of four stocks trading near their 52-week highs with a high chance of carrying upward price momentum forward, alongside SNX, AMP and NWL.

Why it matters — The item signals that HRMY is among stocks with notable price strength and perceived upside potential, highlighting positive market attention on the company.

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

GlobeNewsWire · 6 Aug 2026neutral

Harmony Biosciences announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Why it matters — The appearance gives HRMY watchers an opportunity to hear directly from management about the company at an investor-focused CNS symposium.

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha reports that Harmony Biosciences has elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline and has become more specific about its business development plans. The author notes that much of the improvement is already reflected in the stock price and has upgraded HRMY from Sell to Hold.

Why it matters — For HRMY watchers, this highlights a shift in the company's pipeline priority toward BP-205 and a view that the stock's valuation already captures much of the recent improvement.

FAQ

Frequently asked questions about HRMY stock

What is the HRMY stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Harmony Biosciences Holdings, Inc. have a median 12-month price target of $48, with estimates ranging from $30 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HRMY stock a buy right now?

Of the 10 analysts covering Harmony Biosciences Holdings, Inc., 6 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Harmony Biosciences Holdings, Inc. 84 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HRMY?

As at 15 Aug 2026, Harmony Biosciences Holdings, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will HRMY stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +24.6% from the last close, and Ticker Nerd's factor model ranks Harmony Biosciences Holdings, Inc. 84 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HRMY stock forecast for 2030?

No analyst covering Harmony Biosciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $70 over the next 12 months.

How has HRMY stock performed over the past year?

Harmony Biosciences Holdings, Inc. returned +4.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Harmony Biosciences Holdings, Inc. do?

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of therapies for neurological disorders.

What is the latest news on HRMY?

The most recent item we track (MarketBeat, 14 Aug 2026): "Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline". At Piper Sandler's virtual CNS Symposium, Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy, and pitolisant lifecycle-management programs.

Company

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on the development and commercialization of therapies for neurological disorders. Its lead product, WAKIX, is a molecule with a novel mechanism of action that increases histamine signaling in the brain by binding to H3 receptors, primarily targeting conditions such as narcolepsy and cataplexy. The company operates in the health technology sector, specifically within pharmaceuticals, providing treatments that address unmet needs in sleep-wake disorders and related neurological conditions. WAKIX has received approvals for expanded indications, including cataplexy in pediatric patients, broadening its therapeutic reach. Harmony Biosciences Holdings, Inc. emphasizes innovative solutions in this specialized market, supporting patients through targeted pharmacotherapies. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company plays a key role in advancing treatments for rare and debilitating neurological diseases.

CEO Dr. Jeffrey M. Dayno M.D. · 293 employees · United States · https://www.harmonybiosciences.com